Auriga Research Partners with PerkinElmer, Inc. to conduct COVID19 testing at Kempegowda International Airport Bengaluru (BIAL)
The dedicated laboratory by Auriga Research equipped with PerkinElmer’s COVID-19 solutions to test inbound and outbound passengers at the airport facility
New Delhi, Dec 24th, 2020 – Auriga Research India Pvt Ltd, Research Wing at Arbro Pharmaceuticals, partnered with global health leader PerkinElmer, Inc. to conduct testing at Kempegowda International Airport Bengaluru (BIAL). The program will include a COVID-19 sample collection booth near the departure gates and have a testing facility on the premises at BIAL.
Mr. Hari Marar, President and CEO, Bangalore International Airport Limited (BIAL) said “The well-being of passengers is our utmost priority and it is our core responsibility to provide for everything to keep them safe and sound. This testing facility is a step towards breaking the chain of community spread of the virus”
The testing facility operated by Auriga Research will use PerkinElmer’s RT-PCR test kits, which are approved by Drugs Controller General of India (DCGI), Indian Council of Medical Research (ICMR) and CE-IVD. Auriga will also use PerkinElmer’s RNA extraction kits and chemagic™ 360 nucleic acid extraction solution for sample preparation. Using PerkinElmer’s comprehensive workflow solution will enable rapid sample processing at higher volumes, thereby decreasing the turnaround time.
Dr. Saurabh Arora, Managing Director, Auriga Research and Arbro Pharmaceuticals, said, “This testing facility is NABL approved and is open to the outbound and inbound passengers for on-demand tests as per the ICMR guidelines with provisions to generate reports in 6-8 hours. This Laboratory will also have the capability to check for surface-oriented COVID-19 infection. This will further help to ensure a safe environment for all the travellers and airport authorities.”
“Considering our long-term relationship with Auriga Research, we are excited and proud to be associated with their airport testing facility. PerkinElmer is one of the few companies that provides full workflow solutions for large scale COVID-19 testing, and we think airport screening will make an impact in slowing the spread,” said Shripad Joshi, President, India, and South Asia, PerkinElmer.
Dr. Saurabh Arora and Mr. Shripad Joshi thanked Mr. Hari and his team for taking up the initiative to join the fight against the pandemic.
PerkinElmer is actively working with speciality and reference diagnostic labs, clinics, hospitals, pharmaceutical and biopharmaceutical labs, academia, and governmental and research institutes to battle the pandemic. PerkinElmer’s comprehensive SARS-CoV-2 offerings span high throughput RNA extraction, RT-PCR, automation
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index.